Mobilization of hematopoietic stem cells with lenograstim in multiple myeloma patients: Prospective multicenter observational study (KMM122)
ConclusionLenograstim can safely and effectively mobilize stem cells in MM autologous settings. (Source: Cancer Medicine)
Source: Cancer Medicine - March 23, 2023 Category: Cancer & Oncology Authors: Eun Hee Jung,
Ja Min Byun,
Dong ‐Yeop Shin,
Young Rok Do,
Jae‐Cheol Jo,
Sang Min Lee,
Sung‐Soo Yoon Tags: RESEARCH ARTICLE Source Type: research
The Impact of HIV Infection on Neoadjuvant and Adjuvant Chemotherapy Relative Dose Intensity in South African Patients with Breast Cancer
CONCLUSIONS: HIV status did not impact neoadjuvant or adjuvant chemotherapy RDI, although patients with breast cancer living with HIV experienced more myelotoxicity during treatment.PMID:36943395 | DOI:10.1093/oncolo/oyad056 (Source: The Oncologist)
Source: The Oncologist - March 21, 2023 Category: Cancer & Oncology Authors: Daniel S O'Neil Oluwatosin A Ayeni Hayley A Farrow Wenlong Carl Chen Georgia Demetriou Ines Buccimazza Sharon Čačala Laura W Stopforth Maureen Joffe Michael H Antoni Gilberto Lopes Yoanna S Pumpalova Witness Mapanga Judith S Jacobson Katherine D Crew Al Source Type: research
Comparison of Biosimilar Filgrastim with Innovator Fligrastim for Peripheral Blood Stem Cells Mobilization, Collection of CD34+ Stem Cells, and Engraftment in Patients Undergoing Autologous and Allogeneic Stem Cell Transplantation: A Single-Center Experience
CONCLUSIONS Our study showed that biosimilar G-CSF (Zarzio®) has comparable efficacy to the original G-CSF (Neupogen®) when used for mobilization in both autologous and allogenic stem cell transplantation and was associated with significant cost saving.PMID:36864713 | DOI:10.12659/AOT.938585 (Source: Annals of Transplantation)
Source: Annals of Transplantation - March 3, 2023 Category: Transplant Surgery Authors: Maha M Islami Mansoor Ahmed Khan Mohammed A Aseeri Majed A Alshamrani Abdelmajid Alnatsheh Sameer Alamoudi Ahmed A Alzahrani Source Type: research
Comparison of Biosimilar Filgrastim with Innovator Fligrastim for Peripheral Blood Stem Cells Mobilization, Collection of CD34+ Stem Cells, and Engraftment in Patients Undergoing Autologous and Allogeneic Stem Cell Transplantation: A Single-Center Experience
CONCLUSIONS Our study showed that biosimilar G-CSF (Zarzio®) has comparable efficacy to the original G-CSF (Neupogen®) when used for mobilization in both autologous and allogenic stem cell transplantation and was associated with significant cost saving.PMID:36864713 | DOI:10.12659/AOT.938585 (Source: Annals of Transplantation)
Source: Annals of Transplantation - March 3, 2023 Category: Transplant Surgery Authors: Maha M Islami Mansoor Ahmed Khan Mohammed A Aseeri Majed A Alshamrani Abdelmajid Alnatsheh Sameer Alamoudi Ahmed A Alzahrani Source Type: research
Comparison of Biosimilar Filgrastim with Innovator Fligrastim for Peripheral Blood Stem Cells Mobilization, Collection of CD34+ Stem Cells, and Engraftment in Patients Undergoing Autologous and Allogeneic Stem Cell Transplantation: A Single-Center Experience
CONCLUSIONS Our study showed that biosimilar G-CSF (Zarzio®) has comparable efficacy to the original G-CSF (Neupogen®) when used for mobilization in both autologous and allogenic stem cell transplantation and was associated with significant cost saving.PMID:36864713 | DOI:10.12659/AOT.938585 (Source: Annals of Transplantation)
Source: Annals of Transplantation - March 3, 2023 Category: Transplant Surgery Authors: Maha M Islami Mansoor Ahmed Khan Mohammed A Aseeri Majed A Alshamrani Abdelmajid Alnatsheh Sameer Alamoudi Ahmed A Alzahrani Source Type: research
Comparison of Biosimilar Filgrastim with Innovator Fligrastim for Peripheral Blood Stem Cells Mobilization, Collection of CD34+ Stem Cells, and Engraftment in Patients Undergoing Autologous and Allogeneic Stem Cell Transplantation: A Single-Center Experience
CONCLUSIONS Our study showed that biosimilar G-CSF (Zarzio®) has comparable efficacy to the original G-CSF (Neupogen®) when used for mobilization in both autologous and allogenic stem cell transplantation and was associated with significant cost saving.PMID:36864713 | DOI:10.12659/AOT.938585 (Source: Annals of Transplantation)
Source: Annals of Transplantation - March 3, 2023 Category: Transplant Surgery Authors: Maha M Islami Mansoor Ahmed Khan Mohammed A Aseeri Majed A Alshamrani Abdelmajid Alnatsheh Sameer Alamoudi Ahmed A Alzahrani Source Type: research
Comparison of Biosimilar Filgrastim with Innovator Fligrastim for Peripheral Blood Stem Cells Mobilization, Collection of CD34+ Stem Cells, and Engraftment in Patients Undergoing Autologous and Allogeneic Stem Cell Transplantation: A Single-Center Experience
CONCLUSIONS Our study showed that biosimilar G-CSF (Zarzio®) has comparable efficacy to the original G-CSF (Neupogen®) when used for mobilization in both autologous and allogenic stem cell transplantation and was associated with significant cost saving.PMID:36864713 | PMC:PMC9990321 | DOI:10.12659/AOT.938585 (Source: Annals of Transplantation)
Source: Annals of Transplantation - March 3, 2023 Category: Transplant Surgery Authors: Maha M Islami Mansoor Ahmed Khan Mohammed A Aseeri Majed A Alshamrani Abdelmajid Alnatsheh Sameer Alamoudi Ahmed A Alzahrani Source Type: research
Comparison of Biosimilar Filgrastim with Innovator Fligrastim for Peripheral Blood Stem Cells Mobilization, Collection of CD34+ Stem Cells, and Engraftment in Patients Undergoing Autologous and Allogeneic Stem Cell Transplantation: A Single-Center Experience
CONCLUSIONS Our study showed that biosimilar G-CSF (Zarzio®) has comparable efficacy to the original G-CSF (Neupogen®) when used for mobilization in both autologous and allogenic stem cell transplantation and was associated with significant cost saving.PMID:36864713 | PMC:PMC9990321 | DOI:10.12659/AOT.938585 (Source: Annals of Transplantation)
Source: Annals of Transplantation - March 3, 2023 Category: Transplant Surgery Authors: Maha M Islami Mansoor Ahmed Khan Mohammed A Aseeri Majed A Alshamrani Abdelmajid Alnatsheh Sameer Alamoudi Ahmed A Alzahrani Source Type: research
Comparison of Biosimilar Filgrastim with Innovator Fligrastim for Peripheral Blood Stem Cells Mobilization, Collection of CD34+ Stem Cells, and Engraftment in Patients Undergoing Autologous and Allogeneic Stem Cell Transplantation: A Single-Center Experience
CONCLUSIONS Our study showed that biosimilar G-CSF (Zarzio®) has comparable efficacy to the original G-CSF (Neupogen®) when used for mobilization in both autologous and allogenic stem cell transplantation and was associated with significant cost saving.PMID:36864713 | PMC:PMC9990321 | DOI:10.12659/AOT.938585 (Source: Annals of Transplantation)
Source: Annals of Transplantation - March 3, 2023 Category: Transplant Surgery Authors: Maha M Islami Mansoor Ahmed Khan Mohammed A Aseeri Majed A Alshamrani Abdelmajid Alnatsheh Sameer Alamoudi Ahmed A Alzahrani Source Type: research
Comparison of Biosimilar Filgrastim with Innovator Fligrastim for Peripheral Blood Stem Cells Mobilization, Collection of CD34+ Stem Cells, and Engraftment in Patients Undergoing Autologous and Allogeneic Stem Cell Transplantation: A Single-Center Experience
CONCLUSIONS Our study showed that biosimilar G-CSF (Zarzio®) has comparable efficacy to the original G-CSF (Neupogen®) when used for mobilization in both autologous and allogenic stem cell transplantation and was associated with significant cost saving.PMID:36864713 | PMC:PMC9990321 | DOI:10.12659/AOT.938585 (Source: Annals of Transplantation)
Source: Annals of Transplantation - March 3, 2023 Category: Transplant Surgery Authors: Maha M Islami Mansoor Ahmed Khan Mohammed A Aseeri Majed A Alshamrani Abdelmajid Alnatsheh Sameer Alamoudi Ahmed A Alzahrani Source Type: research
Comparison of Biosimilar Filgrastim with Innovator Fligrastim for Peripheral Blood Stem Cells Mobilization, Collection of CD34+ Stem Cells, and Engraftment in Patients Undergoing Autologous and Allogeneic Stem Cell Transplantation: A Single-Center Experience
CONCLUSIONS Our study showed that biosimilar G-CSF (Zarzio®) has comparable efficacy to the original G-CSF (Neupogen®) when used for mobilization in both autologous and allogenic stem cell transplantation and was associated with significant cost saving.PMID:36864713 | PMC:PMC9990321 | DOI:10.12659/AOT.938585 (Source: Annals of Transplantation)
Source: Annals of Transplantation - March 3, 2023 Category: Transplant Surgery Authors: Maha M Islami Mansoor Ahmed Khan Mohammed A Aseeri Majed A Alshamrani Abdelmajid Alnatsheh Sameer Alamoudi Ahmed A Alzahrani Source Type: research
Comparison of Biosimilar Filgrastim with Innovator Fligrastim for Peripheral Blood Stem Cells Mobilization, Collection of CD34+ Stem Cells, and Engraftment in Patients Undergoing Autologous and Allogeneic Stem Cell Transplantation: A Single-Center Experience
CONCLUSIONS Our study showed that biosimilar G-CSF (Zarzio®) has comparable efficacy to the original G-CSF (Neupogen®) when used for mobilization in both autologous and allogenic stem cell transplantation and was associated with significant cost saving.PMID:36864713 | PMC:PMC9990321 | DOI:10.12659/AOT.938585 (Source: Annals of Transplantation)
Source: Annals of Transplantation - March 3, 2023 Category: Transplant Surgery Authors: Maha M Islami Mansoor Ahmed Khan Mohammed A Aseeri Majed A Alshamrani Abdelmajid Alnatsheh Sameer Alamoudi Ahmed A Alzahrani Source Type: research
Comparison of Biosimilar Filgrastim with Innovator Fligrastim for Peripheral Blood Stem Cells Mobilization, Collection of CD34+ Stem Cells, and Engraftment in Patients Undergoing Autologous and Allogeneic Stem Cell Transplantation: A Single-Center Experience
CONCLUSIONS Our study showed that biosimilar G-CSF (Zarzio®) has comparable efficacy to the original G-CSF (Neupogen®) when used for mobilization in both autologous and allogenic stem cell transplantation and was associated with significant cost saving.PMID:36864713 | PMC:PMC9990321 | DOI:10.12659/AOT.938585 (Source: Annals of Transplantation)
Source: Annals of Transplantation - March 3, 2023 Category: Transplant Surgery Authors: Maha M Islami Mansoor Ahmed Khan Mohammed A Aseeri Majed A Alshamrani Abdelmajid Alnatsheh Sameer Alamoudi Ahmed A Alzahrani Source Type: research
Cost-efficiency analysis of conversion to biosimilar filgrastim for supportive cancer care and resultant expanded access analysis to supportive care and early-stage HER2+ breast cancer treatment in Saudi Arabia: Simulation study
CONCLUSION: This simulation study demonstrated significant potential cost-savings from biosimilar conversion. These savings provide budget-neutral increased access to supportive and therapeutic cancer care.PMID:36815700 | DOI:10.1080/13696998.2023.2183680 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - February 23, 2023 Category: Health Management Authors: Consuela Cheriece Yousef Mansoor Ahmed Khan Hind Almodaimegh Majed Alshamrani Meteb O Alfoheidy Hana AlAbdalkarim Ahmed AlJedai Anjum Naeem Ivo Abraham Source Type: research
